logo oncology-news

Онкология  >  Новости онкологии

При финансовой поддержке logo MSD Oncology

HER2+ metastatic breast cancer: closing CLEOPATRA results confirm pertuzumab survival benefit

8-year results show an advantage of 16.3 months.